TABLE 1.
Pharmacokinetic dataa
| Administration | Site | AUC (μg · h · ml−1) | Cmax (μg · ml−1) | Tmax (h) | t1/2 (h) | Clearance (liter · h−1) |
|---|---|---|---|---|---|---|
| I.v. | Plasma | 22.9 ± 11.1 | 3.7 ± 0.7 | 1.0 ± 0.2 | 14.3 ± 2.4 | 2.3 ± 0.4 |
| Muscle | 9.5 ± 5.9* | 1.2 ± 0.8 | 1.8 ± 0.6 | |||
| Subcutis | 7.9 ± 4.6* | 1.0 ± 0.5 | 2.0 ± 1.0 | |||
| Saliva | 21.4 ± 5.0 | 5.1 ± 1.4 | 1.0 ± 0.1 | 14.9 ± 2.7 | ||
| Capillary | 22.1 ± 2.0 | 4.2 ± 0.4 | 1.0 ± 0.0 | 12.3 ± 2.1 | ||
| Blister | 16.7 ± 4.1 | 1.7 ± 0.3 | 5.6 ± 4.5 | |||
| P.o. | Plasma | 19.8 ± 1.5 | 3.2 ± 0.6 | 1.6 ± 0.8 | 14.3 ± 2.0 | 2.4 ± 0.4 |
| Muscle | 8.5 ± 2.0* | 0.9 ± 0.2 | 3.2 ± 1.4 | 10.2 ± 1.7 | ||
| Subcutis | 8.0 ± 2.1* | 0.9 ± 0.2 | 2.4 ± 1.7 | 7.5 ± 2.6 | ||
| Saliva | 17.6 ± 2.7 | 3.6 ± 1.0 | 1.7 ± 0.7 | 14.3 ± 3.2 | ||
| Capillary | 18.7 ± 3.1 | 2.7 ± 0.8 | 2.5 ± 3.3 | 12.0 ± 2.2 | ||
| Blister | 12.3 ± 3.3* | 1.6 ± 0.2 | 8.0 ± 3.7 |
a
Pharmacokinetic parameters for venous plasma (0 to 12 h), skeletal muscle and subcutaneous adipose interstitial fluid (0 to 12 h), saliva (0 to 12 h), capillary plasma (0 to 12 h), and cantharides-induced skin blister fluid (0 to 12 h) following administration of moxifloxacin (single i.v. dose of 400 mg over 60 min or p.o. dose of 400-mg tablet) in healthy volunteers (n = 12). The results are presented as means ± SD. *, P < 0.05 versus AUCplasma.